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ucleos(t)ide analogues. Patients were evaluated based on
irologic and serologic response to therapy, and were clas-
iﬁed as patients with a detectable level of HBV DNA and
ndetectable HBV DNA (<1.08 log copies/ml). The muta-
ions associated with HBV drug resistance were investigated
n patients with detectable HBV DNA. Due to resistance, in
his group of patients treatment was change.
Results: In our study group, four patients devel-
ped LAM-associated mutations (rtL180M+rtM204V,
tL180M+rtM204V/I, and 2 present rtM204I), three patients
eveloped ADV-associated mutations (rtA181V+rtN236T;
tN236T and rtA181V), one patient developed ADV+LAM
ssociated mutations (rtL180M+rtA181V+rtN236T) and
ther patient developed ETV-associated mutations
rtL180M+rtT184A+rtS202G+rtM204V). Beside the primary
esistant mutations, various combinations of secondary
nd compensatory mutations conferring resistance to
ucleos(t)ide analogues were detected in 5 (33%) patients.
Conclusion: HBV treatment with nucleoside analogues
esults in the development of mutants strains, leading
o drug resistance. These data suggest an early develop-
ent of ETV resistance in patients with prior LAM and ADV
esistance. Therefore genotypic resistance is important in
onitoring HBV treatment. In conclusion, optimization of
herapy combining LAM and ADV may be a good choice for
atients with hepatitis B who have resistance mutations to
DV or LMV.
oi:10.1016/j.ijid.2010.02.2008
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Background: Over the last few years a new concept
as intoduced a possibility a SVR may indicate cure. VHC-
RN clearence at 6 months after therapy discontinuation
VR (sustained virologic response) is generally assumed as
robable cure. The medical literature shows a signiﬁcative
eduction in the rate of progression to cirrosis and Hep-
tocarcinoma development in patients who achieved SVR
ompared to non responders and relapsers.
Methods: We retrospectively analysed a group of VHC
atients that fulﬁlled histologic criteria for antiviral treat-
ent from 1998 to 2009. We performed VHC ARN PCR
eterminations at baseline, during treatment, in the last
eek of antiviral treatment, every 6 months’ until the 2◦
ear after therapy discontinuation. and once a year further
n. We deﬁned ETR as negative or undetectable ARN VHC
CR in the last week of antiviral treatment.
Results: In our study 38 patients achieved ETR (nega-
ive VHC PCR during the ﬁnal week of IFN treatment). Only
e
i
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patients that achieved ETR showed early relapse in the
ext six months after stopping therapy (so they not achieved
VR). The rest of the patients are not detectable up to the
ast control., in the long term follow up.
Conclusion: In this small group of patients we didn‘t ﬁnd
elapses after 6 months following discontinuation of therapy,
ith a mean follow up of nearly 10 years The period of higest
isk of relapses was the next 12 months after the end of
reatment. The rate of relapses after 24 months of the end
f treatment was very low, as estimated in different studies
etween 1 and 2%.
oi:10.1016/j.ijid.2010.02.2009
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Background: The objectives were to estimate the preva-
ence of hepatitis A among children and adolescents from
outh and southeast region of Brazil and to identify
ndividual-, household- and area-levels factors associated
ith hepatitis A infection.
Methods: This population-based survey was conducted
n 2007—2008 and covered individuals aged between 5 and
9 years. A stratiﬁed multistage cluster sampling technique
ith probability proportional to size was used to select
.054 individuals aged between 5 and 19 years living in
he State capitals of 7 states in the study regions. The
ample was stratiﬁed according to age (5—9 and 10- to
9-years-old) and capital within each region. Individual-
nd household-level data were collected by interview at
he home of the individual. Variables related to the area
ere retrieved from census tract data. The outcome was
otal antibodies to hepatitis A virus detected using com-
ercial EIA. The associations between HAV infection and
ndependent variables were assessed using the odds ratio
nd corrected for the random design effect and sampling
eight. Multilevel analysis was performed by GLLAMM using
tata 9.2.
Results: The prevalence of hepatitis A infection in the
—9 and 10—19 age-group was 20,6 and 37,7%, respec-
ively for the Southeast and, 18,9 and 34,5%, respectively
or the South. A trend for the prevalence of HAV infec-
ion to increase according to age was detected in all sites.
ultilevel modeling showed that variables relating to differ-
nt levels of education were associated with HAV infection
n all sites. The multilevel model showed that individual,
ousehold- and area-level variables are independently asso-
iated with HAV infection. Age is an important predictor of
